These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1455 related articles for article (PubMed ID: 27877033)

  • 21. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
    Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis.
    Oba Y; Lone NA
    Int J Chron Obstruct Pulmon Dis; 2014; 9():469-79. PubMed ID: 24872685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM; Thomas EC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
    Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A; Jones PW; Dalvi PS; McAulay K; McIver T; Dissanayake S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity.
    Feng JX; Lin Y; Lin J; He SS; Chen MF; Wu XM; Xu YZ
    J Korean Med Sci; 2017 Mar; 32(3):439-447. PubMed ID: 28145647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What pulmonologists think about the asthma-COPD overlap syndrome.
    Miravitlles M; Alcázar B; Alvarez FJ; Bazús T; Calle M; Casanova C; Cisneros C; de-Torres JP; Entrenas LM; Esteban C; García-Sidro P; Cosio BG; Huerta A; Iriberri M; Izquierdo JL; López-Viña A; López-Campos JL; Martínez-Moragón E; Pérez de Llano L; Perpiñá M; Ros JA; Serrano J; Soler-Cataluña JJ; Torrego A; Urrutia I; Plaza V
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1321-30. PubMed ID: 26270415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
    Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome.
    Lim HS; Choi SM; Lee J; Park YS; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Lee CH
    Ann Allergy Asthma Immunol; 2014 Dec; 113(6):652-7. PubMed ID: 25280465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
    Strange C; Walker V; DePietro M; Tong J; Kurlander J; Carlyle M; Millette LA; Wittbrodt E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1377-1388. PubMed ID: 31303751
    [No Abstract]   [Full Text] [Related]  

  • 36. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.